Opioid receptor targeting
US6359111B1 · kind B1 · utility
45Cited by
23References
17Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 27, 1999 |
| Grant date | Mar 19, 2002 |
| Priority date | — |
| Expiry date | May 27, 2019 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K51/0497
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A compound comprising a ligand portion which has binding affinity for an opioid receptor, and a therapeutically or diagnostically effective group selected from radionuclide chelating agents, fluorochromes, toxins, drugs, polyboron moieties, proteins, biological response modifiers, chemical moieties capable of binding to other molecules of interest, and radioisotopes selected from therapeutically effective alpha and beta emitters, and diagnostically effective gamma emitters. The compound may be used in a method of treating cancer, and in a method of imaging opioid receptors either inside or outside of the central nervous system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.